Market Snapshot and Strategic Outlook for Hybio Pharmaceutical Ltd.
Trading Overview
- Last 24‑hour performance: Flat, 0 % movement.
- Current trading price: CNY 26.5 per share.
- Outstanding shares: 837.3 million.
- Market capitalization: CNY 22 billion.
- 24‑hour volume: Approximately CNY 2.1 billion.
- Year‑to‑date change: Up 11.49 % since the end of last month.
- 200‑day simple moving average: CNY 23.24.
- 52‑week range: High of CNY 27.70 (13 Aug 2026); low of CNY 16.23 (4 Mar 2026).
Recent Guidance
Hybio Pharmaceutical Ltd has released a forward‑looking briefing on its first three‑quarter earnings for 2026. Management projects a significant lift in net profit, citing robust growth across its core product lines and expanded overseas sales. Key drivers identified include:
- Specialty Active Pharmaceutical Ingredients (APIs): Rising demand for high‑purity polypeptide APIs.
- Upstream Manufacturing Materials: Steady supply chain efficiencies.
- Cost Optimization Initiatives: Ongoing process improvements and lean manufacturing.
- Operational Efficiency Gains: Targeted enhancements in R&D productivity and production scalability.
While the company acknowledges broader industry headwinds, it underscores a commitment to maintaining competitive positioning through innovation and market penetration.
Peer Performance Snapshot (Last 24 Hours)
| Stock | Ticker | 24‑Hour Movement | Current Price | Market Cap (CNY bn) | P/E Ratio |
|---|---|---|---|---|---|
| Aoshikang | 002913.SZ | 0 % | 86.07 | 26.3 | 136.99 |
| Xinfengming | 603225.SS | 0 % | 16.24 | 26.3 | 14.59 |
| Zhejiang Sanmei Chemical | 603379.SS | 0 % | 44.28 | 26.4 | 16.02 |
| Jiangxi Zhengbang Tech | 002157.SZ | 0 % | 2.84 | 26.4 | – |
| China Film | 600977.SS | 0 % | 14.33 | 26.4 | 230.5 |
China Film’s recent performance is noteworthy due to its involvement in AI‑driven short‑form video and drama content. The company has benefited from a surge in investor interest following the success of ByteDance’s short‑form drama application and the launch of AI‑enhanced long‑form productions. These developments signal a broader trend of artificial intelligence integration within China’s media and entertainment sector.
Company Profile
Hybio Pharmaceutical Co., Ltd., founded in 1998 and headquartered in Shenzhen, specializes in the R&D, manufacturing, and commercialization of polypeptide drugs. Its product portfolio spans:
- Digestive System Agents
- Immune Modulators
- Parathyroid Hormone (PTH) and Calcium Metabolism Modulators
- Hormonal and Endocrine Modulators
- Fibrinogen‑Derived (FD) Products for Circulatory/Blood Systems
- Antiviral Agents
- Hemostatic Products
In addition to finished dosage forms, Hybio offers peptide Contract Research Organization (CRO) and Contract Manufacturing Organization (CMO) services, alongside API production. The company’s IPO was launched on 7 April 2011 and its shares trade on the Shenzhen Stock Exchange. For further details, visit the official site at www.hybio.com.cn .
